Funding for this research was provided by:
Health Canada Substance Use and Addictions Program grant (1718-HQ-000024)
Michael Smith Foundation for Health Research
University of British Columbia
Canada Research Chairs program through a Tier 1 Canada Research Chair in Inner City Medicine
Received: 14 December 2020
Accepted: 9 June 2021
First Online: 27 June 2021
: The Providence Health Care/University of British Columbia research ethics board granted approval for this study as part of a larger point-of-care drug checking program evaluation.
: Not applicable.
: Dr. Wood is a consultant to Numinus Wellness a mental health company exploring the use of psychedelic medicines.